Frovatriptan succinate anhydrous

Base Information

• Chemical Name: Frovatriptan succinate anhydrous
• CAS No.: 158930-09-7
• Molecular Formula: C18H23N3O5
• Molecular Weight: 361.3923
• UNII: 36K05YF32G
• DSSTox Substance ID: DTXSID90166543
• Wikidata: Q27256576
• ChEMBL ID: CHEMBL1200371
• Mol file: 158930-09-7.mol

Synonyms:158930-09-7;Frovatriptan succinate anhydrous;Frovatriptan (succinate);(R)-3-(Methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide succinate;36K05YF32G;butanedioic acid;(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide;UNII-36K05YF32G;SCHEMBL672784;SB 209509ax;CHEMBL1200371;HY-B1658B;AMY4157;DTXSID90166543;s5848;AKOS015899244;AC-4258;CS-0021310;FROVATRIPTAN SUCCINATE ANHYDROUS [MI];F87145;EN300-23524583;Q27256576;(R)-3-(Methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamidesuccinate;(+)-(R)-2,3,4,9-TETRAHYDRO-3-(METHYLAMINO)-1H-CARBAZOLE-6-CARBOXAMIDE BUTANEDIOATE (1:1);(3R)-3-(METHYLAMINO)-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-6-CARBOXAMIDE;BUTANEDIOIC ACID;1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-, butanedioate (1:1);1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-, butanedioate (1:1)

Chemical Property of Frovatriptan succinate anhydrous

Chemical Property:

• Vapor Pressure: 1.01E-10mmHg at 25°C
• Boiling Point: 515.2 °C at 760mmHg
• Flash Point: 265.4 °C
• PSA: 146.50000
• LogP: 2.55440
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 5
• Exact Mass: 361.16377084
• Heavy Atom Count: 26
• Complexity: 426

Purity/Quality:

99% ^*data from raw suppliers

FrovatriptanSuccinate >98% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O
• Isomeric SMILES: CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O
• Description: Frovatriptan succinate was launched as an oral treatment for acute migraine attacks with or without aura in adults. It is the eighth member of the “triptan” class. Frovatriptan is a conformationally-restricted analog of the 5-HT1-receptor agonist 5-carboxytryptamine which can be prepared in six steps. The key intermediate (R)-6-cyano-3-N-methylamino- 1,2,3,4-tetrahydrocarbazole is obtained by Fischer reaction of 4-cyanophenylhydrazine with the appropriate ketone followed by resolution using L-pyroglutamic acid. This drug acts as a dual 5-HT1D/1B receptor partial agonist and has high and selective affinity for 5HT1B and 5-HT1D receptors in cranial vessels. It has no significant activity at 5-HT2, 5-HT3, 5-HT4, α-adrenergic, histaminergic or GABAA receptors. Frovatriptan is also a moderately potent full agonist at 5-HT7 receptors, which have a dilatory action and are expressed in the human coronary artery. In vitro studies appear to indicate frovatriptan’s functional selectivity for cerebral circulation as shown by the concentrations needed to induce threshold contractile activity and maximum response in basilar arteries as compared with coronary arteries. Frovatriptan is mainly metabolized by CYPlA2 and most of its metabolites are excreted renally. Co-administration of frovatriptan with the monoamine oxidase-A inhibitor moclobemide or with the potent CYPlA2 inhibitor fluvoxamine did not affect its pharmacokinetics parameters. Although frovatriptan has a poor bioavailability (24- 30%), it has a very long half-life compared to other triptans (25 h) and has an onset of action and efficacy similar to those of naratriptan. The most striking features of this drug are the low headache recurrence rate, which is one of the lowest among the triptans and which may be attributed to its long half-life, and excellent tolerance profile. No significant effect on the cardiovascular system was seen after administration of a single oral dose of 14 fold the therapeutic dose of frovatriptan.
• Therapeutic Function: Migraine therapy